ADA 81st Symposium: Cardiovascular and Kidney Outcomes in Efpeglenatide

Click here to subscribe to Diabetesincontrol.com

Categories: Health | Welfare Health Education Age: 14 until 18 year 19 until 30 year 31 until 64 years

3 years ago

Html
Text

Plus: insulin & lipids: more

Saturday, July 24, 2021 : Issue #1152

TOP STORIES - Diabetes News & Research

ADA 81st Symposium: Cardiovascular and Kidney Outcomes in Efpeglenatide
How are Diabetes and Cardiovascular Disease Related?
Effects of Basal Insulin on Lipids vs. Other Antihyperglycemics

Letter from the Editor
The number of GLP1-RA’s has grown over the past few years, and the fact that there are still new ones working their way towards approval can be viewed as a measuring stick to how important this class will be for treating diabetes now and going forward. Each time a new class member comes out, the manufacturer is forced to find a way to differentiate itself from the rest of the class. This could be as simple as a better delivery device, or looking for new benefits in patient care. This week our intern Alan Martinez, PharmD Candidate, USF College of Pharmacy, takes a look at Efpeglenatide, the newest GLP1-RA, and the unique benefits for cardiovascular and renal protection, in our Laterpay feature.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief

Did You Know? Controlling Blood Glucose Earlier Provides a Longer Life:

People with diabetes are 2 to 4 times more likely than others to develop cardiovascular disease. Because this risk is so high, cardiovascular disease remains the most common cause of death in people with diabetes, with more than 50% of deaths coming from CVD.
A study in Diabetes Care looked at the potential impact of instituting earlier glucose control compared with delayed glucose-lowering therapy. They found that patients with type 2 diabetes who maintained a one percentage point lower A1C from the time they were diagnosed had an 18.8% decreased risk for all-cause mortality 10 to 15 years later, while those who waited ten years after diagnosis to maintain a lower A1C had a 2.7% reduced all-cause mortality risk. Maintaining a lower A1C level shortly after diagnosis also was associated with greater reductions in risk for myocardial infarction. The glycemic legacy effects seen in type 2 diabetes are mainly explained by historical HbA1c values having a greater impact than current clinical outcomes. Early detection of diabetes and intensive glucose control from the time of diagnosis is essential to maximize the reduction of the long-term risk of glycemic complications. Maybe it is time for the ADA to recommend pharmaceutical help for those with prediabetes. and lower the diagnosis of diabetes from 7% to 5.7%? Diabetes Care June 2021

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Torré Anderson, II, Fourth Year Doctor of Pharmacy Candidate, Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health

Ashley Ball, PharmD Candidate, LECOM-School of Pharmacy

Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy

Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy

Anina Pham, PharmD. Candidate, Lake Erie College of Osteopathic Medicine, College of Pharmacy

Jessica Rogers, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com

©2021 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control
2093 Philadelphia Pike #8370
Claymont, DE, 19703, United States
DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

ADA 81st Symposium: Cardiovascular and Kidney Outcomes in Efpeglenatide

Saturday, July 24, 2021 : Issue #1152

TOP STORIES - Diabetes News & Research

TOP STORIES - Diabetes News and Research

Did You Know? Controlling Blood Glucose Earlier Provides a Longer Life:

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Share on

Other newsletters from Diabetesincontrol.com

Related newsletters

View other categories